Neoadjuvant Pembrolizumab is Active in Surgically Resected Head and Neck Cancer
Sarah Palackdharry(University of Cincinnati), Trisha M. Wise‐Draper(University of Cincinnati), Laura Conforti(University of Cincinnati), Francis P. Worden(Georgetown University), Matthew Old, Keith Casper(University of Michigan), Yash Patil(University of Cincinnati), Neal Dunlap(University of Louisville), Vinita Takiar(University of Cincinnati), Nooshin Hashemi Sadraei(University of Cincinnati), Maura L. Gillison(The University of Texas MD Anderson Cancer Center), Jonathan R. Mark(University of Cincinnati), Michelle Mierzwa(University of Michigan), Edith M. Janssen(Springhouse), Paul E. O’Brien(Medical University of South Carolina), Keith Wilson(Cardiff University), Randy Butler(University of Cincinnati), B. Huth(University of Cincinnati), Ezra E.W. Cohen(Moores Cancer Center), John C. Morris(Alzheimer's Association), Benyamin Yaniv(University of Massachusetts Chan Medical School)
International Journal of Radiation Oncology*Biology*Physics
March 16, 2018
Cited by 1
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Incidence Trends for Human Papillomavirus–Related and –Unrelated Oral Squamous Cell Carcinomas in the United States
|Journal of Clinical Oncology|2008|1.6k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k